» Articles » PMID: 31852764

Laboratory Analysis of an Outbreak of Candida Auris in New York from 2016 to 2018: Impact and Lessons Learned

Abstract

is a multidrug-resistant yeast which has emerged in health care facilities worldwide; however, little is known about identification methods, patient colonization, environmental survival, spread, and drug resistance. Colonization on both biotic (patients) and abiotic (health care objects) surfaces, along with travel, appear to be the major factors for the spread of this pathogen across the globe. In this investigation, we present laboratory findings from an ongoing outbreak in New York (NY) from August 2016 through 2018. A total of 540 clinical isolates, 11,035 patient surveillance specimens, and 3,672 environmental surveillance samples were analyzed. Laboratory methods included matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) for yeast isolate identification, real-time PCR for rapid surveillance sample screening, culture on selective/nonselective media for recovery of and other yeasts from surveillance samples, antifungal susceptibility testing to determine the resistance profile, and Sanger sequencing of the internal transcribed spacer (ITS) and D1/D2 regions of the ribosomal gene for genotyping. Results included (a) identification and confirmation of in 413 clinical isolates and 931 patient surveillance isolates as well as identification of 277 clinical cases and 350 colonized cases from 151 health care facilities, including 59 hospitals, 92 nursing homes, 1 long-term acute care hospital (LTACH), and 2 hospices, (b) successful utilization of an in-house developed real-time PCR assay for the rapid screening of patient and environmental surveillance samples, (c) demonstration of relatively heavier colonization of in nares than in the axilla/groin, and (d) predominance of the South Asia clade I with intrinsic resistance to fluconazole and elevated MIC to voriconazole (81%), amphotericin B (61%), flucytosine (5FC) (3%), and echinocandins (1%). These findings reflect greater regional prevalence and incidence of and the deployment of better detection tools in an unprecedented outbreak.

Citing Articles

The multidrug-resistant complex and phylogenetic related species: Insights into antifungal resistance mechanisms.

Ramos L, Barbosa P, Lorentino C, Lima J, Braga A, Lima R Curr Res Microb Sci. 2025; 8:100354.

PMID: 39995443 PMC: 11847750. DOI: 10.1016/j.crmicr.2025.100354.


isolates from New York outbreak are highly pathogenic with measurable experimental disease in .

Anower M, Dennis E, Chaturvedi S, Chaturvedi V Microbiol Spectr. 2025; 13(3):e0294223.

PMID: 39912700 PMC: 11878041. DOI: 10.1128/spectrum.02942-23.


The emerging fungal pathogen induces IFNγ to colonize mammalian hair follicles.

Merrill E, Prudent V, Moghadam P, Rodriguez A, Hurabielle C, Wells E bioRxiv. 2025; .

PMID: 39868197 PMC: 11760791. DOI: 10.1101/2025.01.15.632653.


Simulating a travel-related origin of in New York-New Jersey.

Verma R, Kiegle E, Keyel A, Chaturvedi S, Chaturvedi V Microbiol Spectr. 2024; 13(2):e0206524.

PMID: 39699207 PMC: 11792543. DOI: 10.1128/spectrum.02065-24.


: Epidemiology and Antifungal Strategy.

Eix E, Nett J Annu Rev Med. 2024; 76(1):57-67.

PMID: 39656947 PMC: 11808652. DOI: 10.1146/annurev-med-061523-021233.


References
1.
Lockhart S, Etienne K, Vallabhaneni S, Farooqi J, Chowdhary A, Govender N . Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. Clin Infect Dis. 2016; 64(2):134-140. PMC: 5215215. DOI: 10.1093/cid/ciw691. View

2.
Ruiz Gaitan A, Moret A, Lopez Hontangas J, Molina J, Aleixandre Lopez A, Cabezas A . Nosocomial fungemia by Candida auris: First four reported cases in continental Europe. Rev Iberoam Micol. 2017; 34(1):23-27. DOI: 10.1016/j.riam.2016.11.002. View

3.
Chowdhary A, Sharma C, Meis J . Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog. 2017; 13(5):e1006290. PMC: 5436850. DOI: 10.1371/journal.ppat.1006290. View

4.
Zhu Y, Barat S, Borroto-Esoda K, Angulo D, Chaturvedi S, Chaturvedi V . Pan-resistant Candida auris isolates from the outbreak in New York are susceptible to ibrexafungerp (a glucan synthase inhibitor). Int J Antimicrob Agents. 2020; 55(4):105922. DOI: 10.1016/j.ijantimicag.2020.105922. View

5.
Benedict K, Jackson B, Chiller T, Beer K . Estimation of Direct Healthcare Costs of Fungal Diseases in the United States. Clin Infect Dis. 2018; 68(11):1791-1797. PMC: 6409199. DOI: 10.1093/cid/ciy776. View